2019 American Transplant Congress
Blood Group Incompatible Living Donor Kidney Transplantation in Patients with End-Stage Kidney Disease Due to Diabetes Kidney Disease
*Purpose: Diabetes is a growing public health problem, and diabetes kidney disease (DKD) is the most prevalent chronic kidney disease and the major cause of…2019 American Transplant Congress
Exploration of the Stanford Integrated Psychosocial Assessment for Transplant with Psychosocial and Medical Outcomes in Kidney/Kidney-Pancreas Transplant Recipients
*Purpose: The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) is a psychometric instrument designed to improve organ transplant patient selection. However, limited studies have been…2019 American Transplant Congress
A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Background: Utilization of direct-acting oral anticoagulants has become a preferred method for chronic anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).…2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
1Study Group, Hephaistos, Germany, 2Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…2019 American Transplant Congress
Treprostinil as a Bridge Therapy to Heart-Lung Transplants with Severe Pulmonary Arterial Hypertension
*Purpose: Heart-lung transplants (HLTx) is the only one effective strategy for advanced pulmonary arterial hypertension (PAH) with refractory right heart failure. But limited availability of…2019 American Transplant Congress
Antirejection Efficacy in De Novo Renal Transplant Recipients Receiving Everolimus with a Reduced-Exposure Calcineurin Inhibitor-Based Regimen: 24-Month Results from the TRANSFORM Study
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To compare the antirejection efficacy outcomes of an everolimus+reduced-exposure CNI (EVR+rCNI) vs mycophenolic acid+standard-exposure CNI (MPA+sCNI) regimen in renal transplant recipients (RTxRs) from the…2019 American Transplant Congress
Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients
Tampa General Hospital, Tampa, FL
*Purpose: The use of direct oral anticoagulants (DOACs) has not been fully adopted by the solid organ transplant (SOT) community due to factors including, fluctuating…2018 American Transplant Congress
Pancreas Retransplantation: Outcomes of This Technical and Immunological Challenge over 38 Patients
IntroductionPancreas transplantation is now a mastered technique for patients suffering from severe diabetes. However, a significant number of grafts are lost for technical and immunological…2018 American Transplant Congress
BETA-2 Score is an Excellent Tool for Monitoring of Islet Allograft Function and Early Detection of Transplant Dysfunction
1Surgery, University of Chicago, Chicago; 2Nephrology, Medical University of Gdańsk, Gdańsk, Poland.
After validation of BETA-2 scores in our cohort of patients in relation to standard stimulation tests, we decided to assess the practical utility of BETA-2…2018 American Transplant Congress
Hospitality Houses and Transplant Patients: Assessing the Impact of a Hospitality House Dedicated to Transplant Patients and Their Families
Hospitality houses exclusively for transplant patients and their families are a relatively new concept and their connection to medical outcomes is untested. One hospitality house…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »